BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case

Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell's pivotal Phase 3 study Disease control rate of 50% in evaluable patients treated with the Phase 3 formulation who failed prior antibody-drug conjugate (ADC) therapyNotable responder had failed 4 prior therapies including ADC therapy with metastatic liver tumor "no longer observed" following BriaCell treatment PHILADELPHIA and VANCOUVER, British Columbia, Feb. 07, 2024 (GLOBE NEWSWIRE) -- BriaCel ...